Shadia Jalal

  • 1179 Citations
  • 16 h-Index
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 18 Similar Profiles
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
Lung Neoplasms Medicine & Life Sciences
Pemetrexed Medicine & Life Sciences
Small Cell Lung Carcinoma Medicine & Life Sciences
Caregivers Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Carboplatin Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Publications 2009 2019

  • 1179 Citations
  • 16 h-Index
  • 45 Article
  • 4 Conference contribution
  • 3 Review article
  • 1 Chapter

A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors

Sharman, J. P., Wheler, J. J., Einhorn, L., Dowlati, A., Shapiro, G. I., Hilton, J., Burke, J. M., Siddiqi, T., Whiting, N. & Jalal, S., Jan 1 2019, In : Investigational New Drugs.

Research output: Contribution to journalArticle

Open Access
Testicular Neoplasms

Doppler fluctuation spectroscopy of intracellular dynamics in living tissue

Li, Z., Sun, H., Turek, J., Jalal, S., Childress, M. & Nolte, D. D., Apr 1 2019, In : Journal of the Optical Society of America A: Optics and Image Science, and Vision. 36, 4, p. 665-677 13 p.

Research output: Contribution to journalArticle

Light scattering
light scattering

Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study

Bang, Y. J., Kang, Y. K., Catenacci, D. V., Muro, K., Fuchs, C. S., Geva, R., Hara, H., Golan, T., Garrido, M., Jalal, S., Borg, C., Doi, T., Yoon, H. H., Savage, M. J., Wang, J., Dalal, R. P., Shah, S., Wainberg, Z. A. & Chung, H. C., Jan 1 2019, In : Gastric Cancer.

Research output: Contribution to journalArticle

Open Access
Esophagogastric Junction
Combination Drug Therapy

Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non–small-cell lung cancer: KEYNOTE-021 cohorts D and H

Gubens, M. A., Sequist, L. V., Stevenson, J. P., Powell, S. F., Villaruz, L. C., Gadgeel, S. M., Langer, C. J., Patnaik, A., Borghaei, H., Jalal, S., Fiore, J., Saraf, S., Raftopoulos, H. & Gandhi, L., Apr 1 2019, In : Lung Cancer. 130, p. 59-66 8 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Viral Tumor Antigens
8 Citations (Scopus)

24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer

Borghaei, H., Langer, C. J., Gadgeel, S., Papadimitrakopoulou, V. A., Patnaik, A., Powell, S. F., Gentzler, R. D., Martins, R. G., Stevenson, J. P., Jalal, S., Panwalkar, A., Chih-Hsin Yang, J., Gubens, M., Sequist, L. V., Awad, M. M., Fiore, J., Saraf, S., Keller, S. M. & Gandhi, L., Jan 1 2018, (Accepted/In press) In : Journal of Thoracic Oncology.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma